Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Craig Rogers who wrote (7606)	5/1/1998 1:10:00 PM
From: VLAD	Read Replies (3) \| Respond to of 23519

Bradpalm is a short and he is reffering to a few anti-MUSE abstracts to be presented at the urology meeting. There will also be some very positive presentations on MUSE and the new product. The debate continues. MUSE will do just fine. Notice how the media skews figures by saying that Viagra has captured 95% of the ED market. They fail to make a comparisson of the total average scripts written for MUSE and Caverject before Viagra came out which was small compared to the total for Viagra. Viagra all of a sudden got a lot of truely non ED people into the so called ED pool along with new patients. The actual "capturing" of the market should initially look at the initial pool of men on MUSE or injections who were lost to Viagra and then again we don't know how many tried it and are going back to the needle or MUSE. VLAD